Mylan (NASDAQ:MYL) – Equities research analysts at Leerink Swann raised their Q4 2018 EPS estimates for Mylan in a report issued on Monday, April 16th. Leerink Swann analyst A. Fadia now expects that the company will earn $1.80 per share for the quarter, up from their prior forecast of $1.30. Leerink Swann has a “Outperform” rating and a $44.00 price target on the stock.
A number of other research analysts have also issued reports on the company. JPMorgan Chase set a $53.00 target price on Mylan and gave the stock a “buy” rating in a report on Thursday, April 12th. Cantor Fitzgerald set a $41.00 target price on Mylan and gave the stock a “hold” rating in a report on Wednesday, April 11th. Morgan Stanley set a $50.00 target price on Mylan and gave the stock a “buy” rating in a report on Monday, April 9th. Royal Bank of Canada set a $45.00 target price on Mylan and gave the stock a “hold” rating in a report on Tuesday, April 3rd. Finally, Mizuho lifted their target price on Mylan from $45.00 to $51.00 and gave the stock a “buy” rating in a report on Thursday, March 15th. Eight analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Mylan currently has a consensus rating of “Buy” and a consensus price target of $47.02.
Mylan (NASDAQ:MYL) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $1.43 earnings per share for the quarter, beating analysts’ consensus estimates of $1.41 by $0.02. The business had revenue of $3.24 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Mylan had a net margin of 5.84% and a return on equity of 19.14%. The company’s revenue was down .9% on a year-over-year basis. During the same period in the previous year, the business earned $1.57 earnings per share.
A number of large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp grew its stake in Mylan by 30.3% during the 4th quarter. Bank of New York Mellon Corp now owns 5,334,789 shares of the company’s stock valued at $225,715,000 after acquiring an additional 1,239,089 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Mylan by 20.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,553,480 shares of the company’s stock valued at $111,450,000 after acquiring an additional 612,513 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Mylan during the 4th quarter valued at about $137,023,000. Millennium Management LLC grew its stake in Mylan by 3,005.3% during the 4th quarter. Millennium Management LLC now owns 2,905,317 shares of the company’s stock valued at $122,924,000 after acquiring an additional 3,005,317 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in Mylan by 72.9% during the 4th quarter. Wells Fargo & Company MN now owns 2,560,305 shares of the company’s stock valued at $108,326,000 after acquiring an additional 1,079,696 shares in the last quarter. 84.53% of the stock is currently owned by institutional investors.
In other Mylan news, insider Anthony Mauro sold 12,257 shares of Mylan stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $40.35, for a total transaction of $494,569.95. Following the transaction, the insider now owns 147,435 shares of the company’s stock, valued at approximately $5,949,002.25. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President Rajiv Malik sold 50,000 shares of Mylan stock in a transaction dated Friday, March 2nd. The shares were sold at an average price of $40.91, for a total value of $2,045,500.00. Following the transaction, the president now directly owns 503,751 shares in the company, valued at approximately $20,608,453.41. The disclosure for this sale can be found here. Insiders sold a total of 269,287 shares of company stock worth $11,034,960 in the last three months. 0.69% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This report was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://weekherald.com/2018/04/20/leerink-swann-equities-analysts-lift-earnings-estimates-for-mylan-myl.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.